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Abstract
Introduction and hypothesis The Ophira Mini Sling System
involves anchoring a midurethral, low-tension tape to the
obturator internus muscles bilaterally at the level of the
tendinous arc. Success rates in different subsets of patients
are still to be defined. This work aims to identify which factors
influence the 2-year outcomes of this treatment.
Methods Analysis was based on data from a multicenter study.
Endpoints for analysis included objective measurements: 1-h
pad-weight (PWT), and cough stress test (CST), and
questionnaires: International Consultation on Incontinence
Questionnaire–Short Form (ICIQ-SF) and Urinary Distress
Inventory (UDI)-6. A logistic regression analysis evaluated
possible risk factors for failure.
Results In all, 124 female patients with stress urinary
incontinence (SUI) underwent treatment with the Ophira
procedure. All patients completed 1 year of follow-up, and
95 complied with the 2-year evaluation. Longitudinal analysis
showed no significant differences between results at 1 and
2 years. The 2-year overall objective results were 81 (85.3 %)
patients dry, six (6.3 %) improved, and eight (8.4 %)
incontinent. A multivariate analysis revealed that previous
anti-incontinence surgery was the only factor that significantly
influenced surgical outcomes. Two years after treatment,
women with previous failed surgeries had an odds ratio
(OR) for treatment failure (based on PWT) of 4.0 [95 %
confidence interval (CI) 1.02–15.57).
Conclusions The Ophira procedure is an effective option for
SUI treatment, with durable good results. Previous surgeries
were identified as the only significant risk factor, though
previously operated patients showed an acceptable success
rate.
Keywords Minisling . Ophira procedure . Single-incision
sling . Stress urinary incontinence
Introduction
The understanding of stress urinary incontinence (SUI)
pathophysiology has consistently improved over the past
decade, resulting in the development of many surgical
techniques. Based on the Integral Theory, Petros and Ulmsten
proposed the tension-free vaginal tape (TVT). According to
this theory, a midurethral tape can stabilize the urethra during
straining without modifying urethral mobility [1, 2]. Ulmsten
first introduced the TVT procedure for female SUI in 1995
[1], and it soon became known worldwide, with a reported
cure rate of >80 % [2]. Despite this cure rate, major
complications, such as injuries to the bowel and major blood
vessels, have been described [3].
Palma introduced the Arc-to-Arc minisling as an alternative
to the TVT procedure in 1999 [4]. In 2001, Delorme developed
the transobturator tape (TOT) technique [5] to reduce
perioperative complications related to the blind passage of
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needles in the retropubic space. Several studies reported high
cure and low complication rates for TOT and, based on
preoperative urodynamic findings and postoperative clinical
examination, uroflowmetry, and cough test, the authors
discussed the mechanisms responsible for the success of this
treatment [6, 7]. Continence rate with the transobturator
approach is reportedly similar to that obtained with the
transvaginal retropubic approach [6, 7]. Most of the described
complications of retropubic slings are related to the blind
nature of these procedures [8].
The Ophira Mini Sling System is an innovative anatomical
approach that involves anchoring a midurethral low-tension
tape to the obturator internus muscles bilaterally at the level of
the tendinous arc through a single vaginal incision. Its
rationale is to reinforce the urethropelvic ligament with a
transobturator tape. Although a recent publication has shown
that minislings are as effective in nonobese as in obese
patients, the ideal subset of patients for this procedure is still
to be defined [9]. This study aimed to identify the most suited
subset of patients for the Ophira procedure.
Materials and methods
An international, multicentric, prospective, open-label, single-
arm, clinical study was carried out in two countries to
assess the clinical performance of the Ophira Mini Sling
System for treating female SUI. The local ethical committees
approved the study, and all patients signed written informed
consent. Only patients older than 18 years with clinical and
urodynamic diagnosis of SUI and with absence of neurological
disease and clinically significant detrusor overactivity were
included. Exclusion criteria were urodynamic changes
suggesting a reduction in bladder capacity; bladder compliance
of or suggestive of bladder outlet obstruction; coagulopathies;
pregnancy; history of sensitivity to foreign materials; acute
urinary tract infection; acute vulvovaginitis; sequelae of
exposure to ionizing radiation; use of drugs that can result in
high surgical risk or risk of significant postoperative
complications, including any drug that interferes with blood
clotting; and contraindication to anesthetic procedure. Data
were collected from 124 women, all of whom completed at
least 1 year of follow-up; 95 (76.6 %) completed 2 years of
follow-up. Workup included history, physical examination,
stress test, standardized 1-h pad-weight test (PWT), and
preoperative urodynamic study. Patients were also evaluated
with two validated questionnaires: the International
Consultation on Incontinence Questionnaire–Short Form
(ICIQ-SF), and Urogenital Distress Inventory (UDI-6). During
postoperative follow-up, patients were reviewed at 1, 3, 6, 12,
and 24 months. For this analysis, 12- and 24-month data were
compared to assess the durability of clinical outcomes.
Objective cure of SUI (dry patients) was defined as urinary
leakage <1 g in the 1-h PWT [10], whereas improvement was
defined as leakage <50 % of the preoperative value. Any
greater urinary leakage was defined as treatment failure [11].
Single-incision minislings (SIMS) were used to treat SUI
(Ophira Mini Sling System; Promedon, Córdoba, Argentina)
composed of polypropylene monofilament mesh (type I) and
relies on two self-anchoring polypropylene multipoint fixation
arms for tissue fixation. A retractable insertion guide (RIG) is
used to ensure accurate insertion. The RIG has two fixation
points at its tip that act as an antirotational system (Fig. 1a–c).
The surgical procedure was generally carried out under
local anesthesia, with 20 ml of 2 % lidocaine being injected
at the midurethral point toward the vaginal fornix and
advancing 2 cm into the obturator internus muscles. General
or spinal anesthesia were less commonly used but were
selected for some particular cases. A vertical, 2-cm vaginal
incision was performed 1 cm from the urethral meatus.
Minimal dissection was performed laterally toward the
ascending ramus of the pubic bone, preserving the endopelvic
fascia. Prior to implant insertion, a RIG was connected to a
multipoint fixation arm. Guided by the surgeon’s index finger,
the guide was introduced behind the ascending ramus of the
pubic bone toward the obturator internus muscle, 1 cm above
the vaginal fornix. When the centering mark of the implant
was underneath the urethra, the trigger on the handle was
deployed to release the fixation arm and set it in place. The
design of the multipoint fixation arm provides strong and
stable primary fixation [12]. The same maneuvers were
repeated on the other side. After fine adjustment of the mesh,
the RIG was removed and the vaginal wall closed in the usual
manner (Fig. 2). Cystoscopy was not mandatory but can be
advised for patients with recurrent incontinence or based on
the surgeon’s intraoperative decision. No Foley catheters were
left in place. Patients were discharged immediately after
spontaneous voiding.
Statistical analyses were performed with SPSS® 17
(Chicago, IL, USA). Continuous variables were compared
with Student’s independent t test for transverse analysis and
paired sample test for longitudinal analysis. Categorical
variables were tested with the Χ2 test for transverse analysis
and theMcNemar test when comparing pre- and postoperative
values for the same subset of patients. Odds ratios (OR) for
treatment failure at 2 years were also calculated. The main
analysis was done to identify baseline factors that could
predict surgical failure. For this purpose, an exploratory
univariate analysis was performed, and posteriorly, a
multivariate model was constructed (logistic regression), with
variables of age, parity, body mass index (BMI), and Valsalva
leak-point pressure (VLPP). A complementary longitudinal
analysis was carried out to assess outcome stability over time.
Data from the 1-and 2-year follow-ups were compared to
fulfill this requirement. The level of statistical significance
was fixed at <0.05 for all comparisons.
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Results
One hundred and twenty-four patients completed 1 year of
follow-up, and 95 complied with the 2-year follow-up
evaluation. Relevant patient variables are shown in Table 1.
Surgeries were done under local anesthesia in 90 (72.6 %)
cases. Mean [standard deviation (SD)] operative time was
17.0 (7.1) min.
Results from the longitudinal overall analyses are presented
in Table 2. There were no significant differences between 1-
and 2-year follow-up data for mean PWT and CST or mean
ICIQ-SF and UDI-6 scores.
To evaluate the effects of baseline factors on Ophira
procedure outcomes, an exploratory univariate analysis was
done prior to a logistic regression analysis, both summarized
in Table 3. The numerical variables of age, parity, BMI, and
VLPP were transformed in dichotomous variables for these
analyses. The two categories for each new variable were as
follows: age ≥60 and <60 years, BMI ≥30 and <30 kg/m2,
parity ≥3 and <3 gestations, and VLPP ≥60 and <60 cmH2O.
Univariate analysis showed that only one factor was
significantly associated with surgical failure: previous anti-
incontinence surgeries (OR 4.0, p =0.032). This finding was
also confirmed after running a logistic regression model, where
previous anti-incontinence surgeries remained the only variable
significantly associated with surgical failure (OR 7.7, p =0.04).
After the identification of previous surgeries as the only
risk factor for surgical failure, the 2-year results were
segmented according to this factor. Figure 3 depicted the
percentages of cured, improved and failed cases within the
following groups: overall results, naïve and previously
operated patients. Table 4 showed the comparison of failure
rates between those patients who received a previous anti-
incontinence surgery and those who did not. Naïve women
achieved a significantly higher success rate than did patients
who had previously undergone surgery according both to
PWT and CST (p =0.032 and p =0.038 respectively). On the
other hand, there was not a statistically significant difference
between these groups in UDI-6 scores. The mean (SD) UDI-6
score for the previously operated women was 2.5 (3.1) and for
naïve patients 1.4 (1.6), p =0.07.
Within the operating room, three patients had symptoms of
lidocaine hydrochloride overdose for which they were treated
conservatively. One woman who underwent local anesthesia
experienced severe intraoperative pain and needed intravenous
sedation. There was no severe intraoperative bleeding or organ
perforation (urethra, bladder, bowel, vessels). There was no
infection, hematoma, or dyspareunia during follow-up. Sling
exposure was observed in four patients (3.2 %), all <0.5 cm in
diameter. Two of these patients were treated with local
estrogen with good results and two by ambulatory resection.
Four patients had urinary retention (3.2 %), which resolved
Fig. 1 a–c Surgical set. Detail
of Ophira Mini Sling System
antirotational tip and retractable
insertion guide
Int Urogynecol J (2014) 25:637–643 639
spontaneously in two and treated by mesh incision in one
and by sling loosening in one. Nine patients (7.3 %)
presented de novo urgency; all were treated initially with
anticholinergics.
Discussion
Understanding physiopathological concepts of SUI has
consistently improved over recent years, and treatment options
have led to the development of many different surgical
techniques. In the past decade, minimally invasive synthetic
slings have replaced Burch colposuspension to become the
preferred technique for treating SUI [13, 14]. The driving aim
ofminislings is to reduce complications. In an attempt to reduce
major problems, a new means of anatomical reconstruction of
urethral support has been described; namely, the tissue fixation
system. This reconstruction is achieved by bilaterally anchoring
a low-tension suburethral tape to the obturator internus muscles
at the level of the tendinous arc [8]. This procedure minimizes
injuries to bowel and major vessels.
In our first study of the SIMS in 1999, we used bovine
pericardium and obtained good initial results; however, there
was an unacceptable rate of extrusion after 6 months [4]. This
problem was later confirmed by a clinical trial using bovine
Fig. 2 a Local anesthesia; b vaginal incision; c dissection laterally toward the ascending ramus of the ischiopubic bone; d , e mesh insertion; f
intraoperative stress test; g removal of retractable insertion guide; h fine adjustment of the mesh; i end of the procedure
Table 1 Relevant baseline clinical variables for all participants (n =124)
Variables Results
Previous anti-incontinence surgeries, n (%) 35 (28.2)a
Age, mean (SD) [years] 54.8 (9.9)
Previous gestation, mean (SD) 3.0 (2.0)
Postmenopause, n (%) 80 (64.5)
VLPP, median (range) 77.0 (25.0–147.0)
Mixed urinary incontinence, n (%) 51 (41.1)
Body mass index, kg/cm2, mean (SD) [] 27.9 (4.6)
a Twenty-eight of these patients reached 2-year follow-up. This is the
number used for further analysis of naïve and previously operated patients
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pericardial slings in which a 90 % rate of postoperative
complications was reported [15]. Persisting with the principle
of restoring the urethropelvic ligament, we reported the results
of using porcine small-intestinal submucosa in 25 patients in
2001 [16]. The Arc-to-Arc mini sling using swine intestinal
submucosa produced 60 % good results in the long term
(6 years’ follow-up) [17]. In addition to the use of a single
incision, other valuable advantages of this procedure are that it
is generally performed under local anesthesia and is a quick
and truly outpatient procedure.
A recently published meta-analysis compared SIMS with
both retropubic and transobturator standard midurethral slings
(SMUS) [18]. It is important to mention that 71 % of patients
in the SIMS group received TVT Secur, the first SIMS
commercially available, which has been associated with poor
results. Moreover, a previous experimental study that
highlighted the key importance of an effective primary
fixation system for achieving good results with minislings
showed that TVT Secur in particular is associated with
delayed and less intense adherence to host tissue after
implantation [12]. In subsequent studies, a later generation
of SIMS showed substantially better results than TVT Secur.
In these later series, the Ophira and Miniarc procedures
produced comparable results [19–21].
Table 2 Comparison between objective and subjective 1- and 2-year follow-up outcomes
Variables Preoperative (n=124) 1 year (n=124) 2 years (n=95) P value (1 vs 2 years)
1-h PWTa,b Mean (SD) 12.5 (15.4) 1.4 (5.9) 2.2 (9.1) 0.477c
Dry, n (%) NA 103 (83.1) 81 (85.3)
Improvement, n (%) NA 9 (7.3) 6 (6.3) 0.368d
Failure, n (%) NA 12 (9.7) 8 (8.4)
CSTa Negative, n (%) 0 (0) 112 (90.3) 82 (86.3) 0.508d
Positive, n (%) 124 (100) 12 (9.7) 13 (13.7)
ICIQ-SFa Mean (SD) 15.8 (3.9) 3.0 (5.1) 1.9 (4.3) 0.148b
UDI-6a Mean (SD) 9.2 (3.1) 2.3 (3.0) 1.7 (2.2) 0.106b
PWT pad weight test, CST cough stress test, ICIQ-SF International Consultation on Incontinence Questionnaire–Short Form, UDI-6 Urinary Distress
Inventory, SD standard deviation
a Postoperative and preoperative records were compared using Student’s two-tailed, dependent t test for continuous variables andMcNemar test for CST.
All the comparisons resulted in p<0.0005
b For the 1- and 2-year follow-ups, there were four and three missing data; we considered these as failed because the last failure was carried forward
c One- and 2-year comparison with Student’s two-tailed independent t test
d One- and 2-year comparison with Student’s independent t test (PWT) and McNemar-Bowker test (CST)
Table 3 Univariate and multivariate analysis
Factor Nfailed/Nfactor (%) Univariate analysis Multivariate analysis
OR (95 % CI) P value OR (95 % CI) P value
Previous surgery 5/28 (17.9) 4.00 (1.02–15.57) 0.032* 7.7 (1.1–53.6) 0.04*
Age ≥60 years 3/31 (9.7) 1.26 (0.32–4.85) 0.759
VLPP <60 cmH2O 4/30 (13.3) 4.31 (0.74–25.04) 0.081
BMI ≥30 kg/m2 4/25 (16.0) 2.81 (0.64–12.25) 0.156
Mixed incontinence 2/29 (6.9) 0.74 (0.14–3.91) 0.723
Menopause 6/53 (10.2) 1.83 (0.35–9.62) 0.468
Parity ≥3 3/47 (6.4) 0.56 (0.13–2.49) 0.440
VLPP Valsalva leak-point pressure, BMI body mass index, OR odds ratio, CI confidence interval
a Postoperative and preoperative records were compared using Student’s two-tailed, dependent t test for continuous variables andMcNemar test for CST.
All the comparisons resulted in p<0.0005
b For the 1- and 2-year follow-ups, there were four and three missing data; we considered these as failed because the last failure was carried forward
c One- and 2-year comparison with Student’s two-tailed independent t test
d One- and 2-year comparison with Student’s independent t test (PWT) and McNemar-Bowker test (CST)
*Statistically significant
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However, the ideal patient for a minisling is still to be
determined. To answer this question, we stratified patients as
naïve, those who had previously undergone anti-incontinence
procedures that had failed, and by age, setting the age of
60 years as the threshold.We obtained the best results in naïve
patients (89.6 % cures). For elderly patients, the objective cure
rate was 80.6 %, which resulted in a nonsignificant OR for
failure of 2.0 (95 % 0.55–7.71). Although our results in the
elderly are quite acceptable and not significantly different
from those of younger patients, many studies have reported
less than optimal results in the former subset of patients. In a
previous study, the authors concluded that TVT in elderly
patients (> 70 years) results in less favorable outcomes [22].
Because of low complication rates, bulking agents are
frequently indicated for the elderly and patients who are
unsuitable for surgery, even though they produce lower
continence rates than SMUS [23]. The favorable results in
elderly patients in our study indicate that this rationale (for
bulking agent use) might also be considered for SIMS.
Nevertheless, data from a randomized controlled trial are
necessary to confirm or reject this possibility.
In clinical settings, the risk of failure must be related
to safety. Many studies report an incidence of bladder
perforation of 1–15 % and an average perforation rate of
5 % with a retropubic approach. On the other hand,
transobturator slings have a lower rate of bladder and
urethral injury during needle passage, which generally
occurs in <1 % of patients, but this type of device usually
causes groin pain. Bleeding, another important complication,
occurs mainly during needle passage [13]. Bleeding upon
entry into the retropubic space or the obturator internus
muscles (in the transobturator route) can be difficult to
manage. Moreover, some major complications, such as bowel
and vascular injuries, as well as deaths have been reported [3].
Most of the described major complications are related to the
blind nature of these procedures [8]. In this Ophira study, there
were no cases of severe intraoperative bleeding, organ injury,
or persistent pain. We consider that the absence of major
complications in this series is attributable to reduction of the
main risk factors; namely, reduction in blind passage of
needles, the need for only one incision, and the relatively
small extent of tissue dissection (considerably smaller than
with SMUS).
For patients who had previously undergone surgery, the
success rate was 67.9 % and the OR for failure 4.0 (95 % CI
1.02–15.57). In a prospective study of TVT in 34 women with
recurrent SUI, the cure rate was 82 % [22]. However, several
studies using retropubic or transobturator slings failed to
reproduce this high success rate for recurrent SUI, reporting
cure rates ranging from 62 % to 74 % [24–27]. It is important
to note that patients with good urethral mobility did better than
those with fixed urethras.
To our knowledge, this is the first report of results of
using minislings for recurrent SUI. Our results are similar to
those reported for TVT or TOT in this subset of patients.
Although our overall results are satisfactory, we stress that
we achieved significantly better outcomes in the naïve group
of patients.
In conclusion, the Ophira Mini Sling System is a safe and
effective option for treating SUI and attans durable good
results. The ideal candidates for this technique are naïve
patients; previous surgeries were identified as the only
significant risk factor, though previously operated patients
showed an acceptable success rate.
Table 4 Results stratified according to the risk factor of previous anti-incontinence surgery
Variables (n) Failure according to PWT Positive CST ICIQ-SF UDI-6
n (%) P valuea n (%) P valuea Mean (SD) P valueb Mean (SD) P valueb
Previous surgery (28) 5 (17.9) 0.032* 7 (25.0) 0.038* 4.4 (6.4) 0.019* 2.5 (3.1) 0.070
Naïve patients (67) 3 (4.5) 6 (9.0) 0.8 (2.2) 1.4 (1.6)
aΧ2 test
b Independent Student’s t test
*Statistically significant
Fig. 3 Success rates according to pad weight test (PWT) for the
segmented sample
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